Sociedad Americana de Hirudoterapia

Clinical Efficacy of Leech Therapy (Ta'lq al-'Alaq) in Eczema (Nr Frs): An Open-Label Single-Arm Clinical Study

Research article published in Alternative therapies in health and medicine (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportResistencia antimicrobianaEnsayos clínicosUlla P BS et al. · Alternative therapies in health and medicine, 2025

Abstract

BACKGROUND: Eczema, known as Nār Fārsī in Unani medicine, is a chronic skin disorder characterized by intense pruritus, dryness, and scaling of skin, along with periodic flares and remissions. Unani literature recognizes it as a disorder caused by safrāwī (bilious) humor. Conventional treatment relies on emollients, humectants, and anti-inflammatory drugs. Unani medicine recommends the expulsion of morbid matter by local blood-letting or oral therapies. Leech therapy, used in many traditional medicine systems for centuries, is a method of expulsion of morbid humors from a disease site. It is prescribed for diseases of joints, skin, the nervous system, etc. Contemporary research has identified many bioactive enzymes and proteins in leech saliva that have anti-inflammatory, analgesic, vasodilatory, antimicrobial, and many other effects. PRIMARY STUDY OBJECTIVE: This study aimed to assess the efficacy and safety of leech therapy in eczema patients based on standard parameters. METHODS: An open-label, single-arm clinical study was conducted on 20 patients diagnosed with eczema. INTERVENTION: Four sessions of leech therapy were carried out with a one-week gap in between. PRIMARY OUTCOME MEASURES: The effectiveness of leech therapy was assessed using the Eczema Area and Severity Index (EASI) Score. RESULTS: Statistically significant improvement was observed in the severity of eczema, as reflected in the EASI Score parameters, i.e., redness (P = .0001), edema (P = .0001), excoriation (P = .0022), and lichenification (P = .0001). However, the decrease in total area involved was not statistically significant (P = .24). CONCLUSION: Leech therapy was found to be safe and effective in relieving the severity of eczema. All patients expressed satisfaction with the treatment, without any drop-outs, indicating excellent adherence to the therapy. With further research, leech therapy may provide positive outcomes in eczema in clinical settings, providing relief to the suffering patients.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansLeechingMaleFemaleAdultEczemaMiddle AgedTreatment OutcomeAgedYoung Adult

Resumen

Eczema, known as Nr Frs in Unani medicine, is a chronic skin disorder characterized by intense pruritus, dryness, and scaling of skin, along with periodic flares and remissions.

Por qué esto importa para la hirudoterapia

This open-label, single-arm clinical study evaluated leech therapy in 20 eczema patients who underwent four weekly sessions, measuring outcomes via the Eczema Area and Severity Index (EASI), with statistically significant improvements in redness (P=.0001), edema (P=.0001), excoriation (P=.0022), and lichenification (P=.0001), though reduction in total affected area was not significant (P=.24). This is directly relevant to ASH's domain as a prospective clinical study of medicinal leech therapy for a dermatological condition. However, critical limitations apply: the absence of a control group, blinding, or randomization substantially limits causal inference and the ability to separate placebo or expectation effects from true therapeutic benefit. The sample size is small (n=20) with no long-term follow-up reported.

Citación

Clinical Efficacy of Leech Therapy (Ta'lq al-'Alaq) in Eczema (Nr Frs): An Open-Label Single-Arm Clinical Study

Ulla P BS et al. · Alternative therapies in health and medicine, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.